Join our daily newsletter At The Bell to receive exclusive market insights
Amplia Therapeutics (ASX:ATX) has popped over +40% in lunchtime trades as the company reports its products provide superior outcomes when coupled with chemotherapy, at least in one ‘ACCENT’ trial announced on Thursday.
“The ACCENT trial is evaluating narmafotinib in combination with the chemotherapies gemcitabine and Abraxane in patients with advanced pancreatic cancer,” Amplia wrote on Thursday.
“Sufficient confirmed responses have now been recorded to demonstrate that narmafotinib combined with chemotherapy is superior to chemotherapy alone.”
Its drug, narmafotinib, is currently the subject of a pancreatic cancer trial which has, clearly, been on watchlists. Just look at liquidity.
Driving ATX’s +40% pop on Thursday is a dramatic shift in the number of shares trading hands each day. As of 1pm some 34.2M individual shares have moved on Amplia’s books, but over the last four weeks, the average daily amount has been only 166K.
That kind of effect is notorious for exaggerating share price gains. But Amplia’s good fortunes do also tap into a larger story for 2025 YTD ā that a number of well-known biotech stocks have been, if not outperforming, then offering some good chances to make a few bags.
Currently, Amplia’s 1Y returns are up nearly +30%.
The most recent shock we saw to the healthcare sector was from, unsurprisingly, Donald Trump, who vowed to slash US drug prices.
So far, it’s not entirely clear how that will occur, and part of that uncertainty is perhaps in part why stocks like Telix and Neuren have been bouncing back from the sell-off that news caused.
ATX last traded at 8cps.
Join the discussion: See what HotCopper users are saying about ATX and be part of the conversations that move the markets.
